Treating Nonalcoholic Fatty Liver: Pioglitazone or Vitamin E?
Vitamin E is superior to placebo in treating nonalcoholic steatohepatitis, according to a New England Journal of Medicine study. Pioglitazone, although showing some efficacy, did not achieve statistically significant results.
Researchers, pursuing earlier findings that thiazolidinediones and antioxidants can lead to improvements in fatty liver, randomized some 250 nondiabetic patients with nonalcoholic steatohepatitis to 2 years’ treatment with either pioglitazone, vitamin E, or placebo. Improved histologic findings were the study’s primary outcome.
Liver biopsies showed that vitamin E recipients had a higher rate of improvement than those on placebo (43% vs. 19%). The improvement among pioglitazone recipients versus placebo did not reach statistical significance (34% vs. 19%). Both treatments reduced alanine and aspartate aminotransferase levels significantly from baseline values.
To view article, click? HERE
No comments:
Post a Comment